Aurobindo Pharma Unit CuraTeQ Secures Key Health Canada Approval for Dyrupeg Biosimilar

HEALTHCAREBIOTECH

Overview

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, achieved a significant regulatory milestone with Health Canada granting a Notice of Compliance for its biosimilar drug, Dyrupeg. This approval validates the product's safety, efficacy, and quality, bolstering CuraTeQ's biologics portfolio.

Health Canada Approves Aurobindo's Dyrupeg Biosimilar

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has achieved a significant regulatory milestone. The company announced Friday that its biologics arm secured a Notice of Compliance (NOC) from Health Canada for Dyrupeg, a biosimilar drug. This approval signifies Health Canada's confirmation of the product's adherence to stringent safety, efficacy, and quality standards following a comprehensive review.

Strengthening the Biologics Portfolio

Dyrupeg represents CuraTeQ's key biosimilar offering. The NOC from Health Canada validates the thorough review process, confirming the drug meets established regulatory benchmarks. This development marks a crucial step in expanding CuraTeQ's presence in the international biologics market.

Recent Corporate Developments

This approval follows a series of strategic moves by Aurobindo Pharma. Earlier this month, the company strengthened its domestic operations by acquiring Khandelwal Laboratories' non-oncology prescription business for ₹325 crore, adding 23 brands and approximately 470 employees. In December, CuraTeQ Biologics ended a biosimilar agreement with BioFactura for product BFI-751, citing portfolio prioritization.

Shares of Aurobindo Pharma Limited closed marginally lower on January 9, down 0.61% at ₹1,198.80 on the NSE.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.